Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for somatostatin

  1. Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

    Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.

    Technology appraisal guidance
    Published
    29 August 2018
    View recommendations

    Sections for TA539

  2. Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver (HTG720)

    Evidence-based recommendations on selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver. This involves injecting tiny radioactive spheres into the blood vessels that supply the liver metastases.

    HealthTech guidance
    Published
    16 May 2024
    View recommendations

    Sections for HTG720

  3. Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

    Discontinued Reference number: GID-TA10033

    Technology appraisal guidance
    Discontinued

  4. Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)

    Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.

    Technology appraisal guidance
    Published
    28 June 2017
    View recommendations

    Sections for TA449